Quebec platelet disorder: Features, pathogenesis and treatment

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 2, 2008, Pages 109-119

  Diamandis, Maria ^a   Veljkovic, D Kika ^a   Maurer Spurej, Elisabeth ^b,c   Rivard, Georges E ^d   Hayward, Catherine P M ^a,e  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

^e MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Blood platelet disorders; Blood platelets; Fibrinolysis; Hemorrhage; Urinary plasminogen activator

Indexed keywords

AMINOCAPROIC ACID; FIBRINOLYTIC AGENT; TRANEXAMIC ACID; UROKINASE;

BLEEDING DISORDER; BLOOD CLOTTING; BLOOD TRANSFUSION; CLINICAL FEATURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HISTORY OF MEDICINE; HUMAN; LABORATORY TEST; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUEBEC PLATELET DISORDER; REVIEW; WESTERN BLOTTING;

BLOOD PLATELET DISORDERS; BLOOD PLATELETS; ECCHYMOSIS; FACTOR V; FIBRINOLYSIS; HUMANS; PLATELET AGGREGATION; URINARY PLASMINOGEN ACTIVATOR;

EID: 39149131665     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3282f41e3e     Document Type: Review

References (73)

1. Tracy PB, Giles AR, Mann KG, Eide LL, Hoogendoorn H, Rivard GE. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet factor V deficiency. J Clin Invest 1984; 74:1221-1228.
2. Hayward CP, Rivard GE, Kane WH, Drouin J, Zheng S, Moore JC, Kelton JG. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood 1996; 87:4967-4978.
3. Hayward CP, Cramer EM, Kane WH, Zheng S, Bouchard M, Masse JM, Rivard GE. Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules. Blood 1997; 89:1243-1253.
4. McKay H, Derome F, Haq MA, Whittaker S, Arnold E, Adam F, et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104:159-165.
5. Kahr WH, Zheng S, Sheth PM, Pai M, Cowie A, Bouchard M, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001; 98:257-265.
6. Sheth PM, Kahr WH, Haq MA, Veljkovic DK, Rivard GE, Hayward CP. Intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder. Thromb Haemost 2003; 90:293-298.
7. Diamandis M, Adam F, Kahr WH, Wang P, Chorneyko KA, Arsenault AL, et al. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. J Thromb Haemost 2006; 4:1086-1094.
8. Janeway CM, Rivard GE, Tracy PB, Mann KG. Factor V Quebec revisited. Blood 1996; 87:3571-3578.
9. Kufrin D, Eslin DE, Bdeir K, Murciano JC, Kuo A, Kowalska MA, et al. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood 2003; 102:926-933.
10. Booth NA, Bachmann F. Plasminogen-plasmin enzyme system. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, editors. Hemostasis and thrombosis. Basic principles and clinical practice. Philadelphia, PA: Lippincott Williams and Wilkins; 2006. pp. 335-364.
11. Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost 2003; 89:610-621.
12. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004; 25:450-455.
13. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67:1215-1223.
14. Singh I, Burnand KG, Collins M, Luttun A, Collen D, Boelhouwer B, Smith A. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation 2003; 107:869-875.
15. Levi M, Moons L, Bouche A, Shapiro SD, Collen D, Carmeliet P. Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. Circulation 2001; 103:2014-2020.
16. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368:419-424.
17. Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990; 62:447-456.
18. Bolon I, Zhou HM, Charron Y, Wohlwend A, Vassalli JD. Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression. Am J Pathol 2004; 164:2299-2304.
19. Bugge TH, Flick MJ, Danton MJ, Daugherty CC, Romer J, Dano K, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1996; 93:5899-5904.
20. Gurewich V. Fibrinolysis: an unfinished agenda. Blood Coagul Fibrinolysis 2000; 11:401-408.
21. Pannell R, Black J, Gurewich V. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. J Clin Invest 1988; 81:853-859.
22. Tripputi P, Blasi F, Verde P, Cannizzaro LA, Emanuel BS, Croce CM. Human urokinase gene is located on the long arm of chromosome 10. Proc Natl Acad Sci U S A 1985; 82:4448-4452.
23. Nagamine Y, Medcalf RL, Munoz-Canoves P. Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost 2005; 93:661-675.
24. Verde P, Boast S, Franze A, Robbiati F, Blasi F. An upstream enhancer and a negative element in the 5′ flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res 1988; 16:10699- 10716.
25. Cannio R, Rennie PS, Blasi F. A cell-type specific and enhancer-dependent silencer in the regulation of the expression of the human urokinase plasminogen activator gene. Nucleic Acids Res 1991; 19:2303-2308.
26. Nerlov C, Rorth P, Blasi F, Johnsen M. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 1991; 6:1583-1592.
27. Nanbu R, Menoud PA, Nagamine Y. Multiple instability-regulating sites in the 3′ untranslated region of the urokinase-type plasminogen activator mRNA. Mol Cell Biol 1994; 14:4920-4928.
28. Lee W, Mitchell P, Tjian R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 1987; 49:741-752.
29. Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H, et al. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998; 77:128-137.
30. Ibanez-Tallon I, Ferrai C, Longobardi E, Facetti I, Blasi F, Crippa MP. Binding of Sp1 to the proximal promoter links constitutive expression of the human uPA gene and invasive potential of PC3 cells. Blood 2002; 100:3325-3332.
31. Marshall BC, Xu QP, Rao NV, Brown BR, Hoidal JR. Pulmonary epithelial cell urokinase-type plasminogen activator. Induction by interleukin-1 beta and tumor necrosis factor-alpha. J Biol Chem 1992; 267:11462-11469.
32. Godambe SA, Chaplin DD, Takova T, Bellone CJ. Upstream NFIL-6-like site located within a DNase I hypersensitivity region mediates LPS-induced transcription of the murine interleukin-1 beta gene. J Immunol 1994; 153:143-152.
33. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T. Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. J Biol Chem 2004; 279:8567-8576.
34. Besser D, Presta M, Nagamine Y. Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. Cell Growth Differ 1995; 6:1009-1017.
35. Ried S, Jager C, Jeffers M, Vande Woude GF, Graeff H, Schmitt M, Lengyel E. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J Biol Chem 1999; 274:16377-16386.
36. Dayer JM, Vassalli JD, Bobbitt JL, Hull RN, Reich E, Krane SM. Calcitonin stimulates plasminogen activator in porcine renal tubular cells: LLC-PK1. J Cell Biol 1981; 91:195-200.
37. Nagamine Y, Sudol M, Reich E. Hormonal regulation of plasminogen activator mRNA production in porcine kidney cells. Cell 1983; 32:1181-1190.
38. Irigoyen JP, Besser D, Nagamine Y. Cytoskeleton reorganization induces the urokinase-type plasminogen activator gene via the Ras/extracellular signal-regulated kinase (ERK) signaling pathway. J Biol Chem 1997; 272:1904-1909.
39. Bernik MB, Kwaan HC. Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study. J Clin Invest 1969; 48:1740-1753.
40. Kenagy RD, Vergel S, Mattsson E, Bendeck M, Reidy MA, Clowes AW. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vasc Biol 1996; 16:1373-1382.
41. McNeill H, Jensen PJ. A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration. Cell Regul 1990; 1:843-852.
42. Husain SS, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys 1983; 220:31-38.
43. Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257:3276-3283.
44. Darras V, Thienpont M, Stump DC, Collen D. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemost 1986; 56:411-414.
45. Declerck PJ, Van Keer L, Verstreken M, Collen D. An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA. Thromb Haemost 1992; 67:95-100.
46. Nicoloso G, Hauert J, Kruithof EK, Van Melle G, Bachmann F. Fibrinolysis in normal subjects - comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Thromb Haemost 1988; 59:299-303.
47. Park S, Harker LA, Marzec UM, Levin EG. Demonstration of single chain urokinase-type plasminogen activator on human platelet membrane. Blood 1989; 73:1421-1425.
48. Gurewich V, Johnstone M, Loza JP, Pannell R. Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett 1993; 318:317-321.
49. Lenich C, Liu JN, Gurewich V. Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator. Blood 1997; 90:3579-3586.
50. Grau E, Moroz LA. Fibrinolytic activity of normal human blood monocytes. Thromb Res 1989; 53:145-162.
51. Moir E, Booth NA, Bennett B, Robbie LA. Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism. Br J Haematol 2001; 113:72-80.
52. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004; 37:541-548.
53. Pannell R, Gurewich V. Activation of plasminogen by single-chain urokinase or by two-chain urokinase - a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood 1987; 69:22-26.
54. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007; 97:336-342.
55. Manchanda N, Schwartz BS. Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes. J Biol Chem 1991; 266:14580-14584.
56. Petersen LC. Kinetics of reciprocal pro-urokinase/plasminogen activation - stimulation by a template formed by the urokinase receptor bound to poly(D-lysine). Eur J Biochem 1997; 245:316-323.
57. Li C, Zhang J, Jiang Y, Gurewich V, Chen Y, Liu JN. Urokinase-type plasminogen activator up-regulates its own expression by endothelial cells and monocytes via the u-PAR pathway. Thromb Res 2001; 103:221-232.
58. Rao JS, Kahler CB, Baker JB, Festoff BW. Protease nexin I, a serpin, inhibits plasminogen-dependent degradation of muscle extracellular matrix. Muscle Nerve 1989; 12:640-646.
59. Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 1984; 10:24-41.
60. Mullertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976; 159:545-553.
61. Longstaff C, Gaffney PJ. Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. Biochemistry 1991; 30:979-986.
62. Okamoto S, Oshiba S, Mihara H, Okamoto U. Synthetic inhibitors of fibrinolysis: in vitro and in vivo mode of action. Ann N Y Acad Sci 1968; 146:414-429.
63. Hayward CP, Welch B, Bouchard M, Zheng S, Rivard GE. Fibrinogen degradation products in patients with the Quebec platelet disorder. Br J Haematol 1997; 97:497-503.
64. Hayward CP, Rao AK, Cattaneo M. Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia 2006; 12 (Suppl 3):128-136.
65. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70:327-333.
66. Lang IM, Schleef RR. Calcium-dependent stabilization of type I plasminogen activator inhibitor within platelet alpha-granules. J Biol Chem 1996; 271:2754-2761.
67. Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71:220-225.
68. Hayward CP, Weiss HJ, Lages B, Finlay M, Hegstad AC, Zheng S, et al. The storage defects in grey platelet syndrome and alphadelta-storage pool deficiency affect alpha-granule factor V and multimerin storage without altering their proteolytic processing. Br J Haematol 2001; 113:871-877.
69. Weiss HJ, Lages B, Zheng S, Hayward CP. Platelet factor V New York: a defect in factor V distinct from that in factor V Quebec resulting in impaired prothrombinase generation. Am J Hematol 2001; 66:130-139.
70. Levin EG, Loskutoff DJ. Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol 1982; 94:631-636.
71. Camoin L, Pannell R, Anfosso F, Lefevre JP, Sampol J, Gurewich V, Dignat-George F. Evidence for the expression of urokinase-type plasminogen activator by human venous endothelial cells in vivo. Thromb Haemost 1998; 80:961-967.
72. Unkeless JC, Gordon S, Reich E. Secretion of plasminogen activator by stimulated macrophages. J Exp Med 1974; 139:834-850.
73. Vassalli JD, Dayer JM, Wohlwend A, Belin D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med 1984; 159:1653-1668.